CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 1,988.80
-15.30 (-0.76%)
At close: Jul 7, 2026
CORONA Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 14,032 | 11,964 | 10,145 | 8,841 | 6,173 | |
Revenue Growth (YoY) | 17.28% | 17.94% | 14.75% | 43.20% | 7.14% |
Cost of Revenue | 2,719 | 2,431 | 2,333 | 2,156 | 1,495 |
Gross Profit | 11,312 | 9,533 | 7,812 | 6,685 | 4,678 |
Selling, General & Admin | 5,102 | 4,507 | 3,857 | 3,398 | 2,923 |
Other Operating Expenses | 3,269 | 2,619 | 2,394 | 2,004 | 1,576 |
Operating Expenses | 8,751 | 7,498 | 6,534 | 5,606 | 4,704 |
Operating Income | 2,561 | 2,035 | 1,278 | 1,079 | -25.87 |
Interest Expense | -67 | -103.5 | -138.81 | -39.28 | -45.46 |
Interest & Investment Income | 70.6 | 44.1 | 46.65 | 59.75 | 52.41 |
Earnings From Equity Investments | 2.7 | 3.8 | 0.06 | 2.28 | - |
Currency Exchange Gain (Loss) | 24.1 | 6.7 | 4.87 | 5.62 | 4.25 |
Other Non Operating Income (Expenses) | 6.5 | 3.8 | 1.47 | -1.28 | 5.71 |
EBT Excluding Unusual Items | 2,598 | 1,990 | 1,192 | 1,106 | -8.96 |
Gain (Loss) on Sale of Investments | 0.7 | 0.2 | 2.56 | 2.46 | 1.01 |
Gain (Loss) on Sale of Assets | -5.4 | -7.1 | -12.05 | -0.2 | - |
Other Unusual Items | -189.1 | 1.9 | 1.93 | 0.56 | - |
Pretax Income | 2,404 | 1,985 | 1,185 | 1,109 | -7.95 |
Income Tax Expense | 553 | 491 | 279.78 | 259.58 | -3.95 |
Net Income | 1,851 | 1,494 | 905.03 | 849.29 | -4 |
Net Income to Common | 1,851 | 1,494 | 905.03 | 849.29 | -4 |
Net Income Growth | 23.88% | 65.11% | 6.56% | - | - |
Shares Outstanding (Basic) | 61 | 61 | 61 | 58 | 51 |
Shares Outstanding (Diluted) | 61 | 61 | 61 | 58 | 51 |
Shares Change (YoY) | - | - | 4.89% | 14.21% | -16.53% |
EPS (Basic) | 30.27 | 24.43 | 14.80 | 14.57 | -0.08 |
EPS (Diluted) | 30.27 | 24.43 | 14.80 | 14.57 | -0.08 |
EPS Growth | 23.90% | 65.09% | 1.59% | - | - |
Free Cash Flow | 553.5 | 988.3 | -1,296 | 79.42 | 636.98 |
Free Cash Flow Per Share | 9.05 | 16.16 | -21.19 | 1.36 | 12.48 |
Dividend Per Share | 10.000 | 7.310 | 3.700 | 2.770 | 1.140 |
Dividend Growth | 36.80% | 97.57% | 33.57% | 142.98% | -0.26% |
Gross Margin | 80.62% | 79.68% | 77.00% | 75.61% | 75.78% |
Operating Margin | 18.25% | 17.01% | 12.60% | 12.21% | -0.42% |
Profit Margin | 13.19% | 12.49% | 8.92% | 9.61% | -0.07% |
Free Cash Flow Margin | 3.94% | 8.26% | -12.77% | 0.90% | 10.32% |
EBITDA | 2,903 | 2,370 | 1,526 | 1,251 | 154.97 |
EBITDA Margin | 20.69% | 19.81% | 15.04% | 14.15% | 2.51% |
D&A For EBITDA | 341.6 | 334.7 | 247.4 | 172.11 | 180.84 |
EBIT | 2,561 | 2,035 | 1,278 | 1,079 | -25.87 |
EBIT Margin | 18.25% | 17.01% | 12.60% | 12.21% | -0.42% |
Effective Tax Rate | 23.00% | 24.73% | 23.61% | 23.41% | - |
Revenue as Reported | 14,138 | 12,024 | 10,209 | 8,911 | 6,239 |
Advertising Expenses | 1,072 | 1,045 | 903.01 | 850.41 | 656.01 |